Cargando…

Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives

Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regul...

Descripción completa

Detalles Bibliográficos
Autores principales: Faes, Seraina, Demartines, Nicolas, Dormond, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005589/
https://www.ncbi.nlm.nih.gov/pubmed/33791295
http://dx.doi.org/10.3389/fcell.2021.636037
_version_ 1783672140640288768
author Faes, Seraina
Demartines, Nicolas
Dormond, Olivier
author_facet Faes, Seraina
Demartines, Nicolas
Dormond, Olivier
author_sort Faes, Seraina
collection PubMed
description Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies.
format Online
Article
Text
id pubmed-8005589
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80055892021-03-30 Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives Faes, Seraina Demartines, Nicolas Dormond, Olivier Front Cell Dev Biol Cell and Developmental Biology Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005589/ /pubmed/33791295 http://dx.doi.org/10.3389/fcell.2021.636037 Text en Copyright © 2021 Faes, Demartines and Dormond. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Faes, Seraina
Demartines, Nicolas
Dormond, Olivier
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
title Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
title_full Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
title_fullStr Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
title_full_unstemmed Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
title_short Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
title_sort mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005589/
https://www.ncbi.nlm.nih.gov/pubmed/33791295
http://dx.doi.org/10.3389/fcell.2021.636037
work_keys_str_mv AT faesseraina mechanistictargetofrapamycininhibitorsinrenalcellcarcinomapotentiallimitationsandperspectives
AT demartinesnicolas mechanistictargetofrapamycininhibitorsinrenalcellcarcinomapotentiallimitationsandperspectives
AT dormondolivier mechanistictargetofrapamycininhibitorsinrenalcellcarcinomapotentiallimitationsandperspectives